Invention Application
US20160304462A1 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS
有权
作为HDAC抑制剂的3-SPIRO-7-羟基四氢叶酸
- Patent Title: 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS
- Patent Title (中): 作为HDAC抑制剂的3-SPIRO-7-羟基四氢叶酸
-
Application No.: US15130613Application Date: 2016-04-15
-
Publication No.: US20160304462A1Publication Date: 2016-10-20
- Inventor: Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, JR.
- Applicant: Forma Therapeutics, Inc.
- Main IPC: C07D221/20
- IPC: C07D221/20 ; C07D403/04 ; C07D209/96 ; C07D401/04 ; C07D417/06 ; C07D519/00 ; C07D401/06 ; C07D413/06 ; C07D405/04 ; C07D471/04 ; C07D497/10 ; C07D491/107 ; C07D405/06 ; C07D403/06
Abstract:
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Public/Granted literature
- US09630922B2 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors Public/Granted day:2017-04-25
Information query
